Cybrexa Therapeutics
Laurie Tylaska began their work experience in 1985 as a Lab Tech III at the University of Vermont, where they worked until 1991. Laurie then joined Pfizer Global Research and Development as a Senior Scientist in 1992 and held that position until May 2018. In May 2018, they moved to Cybrexa Therapeutics as a Sr Research Scientist. It is not specified when they started working at Pfizer.
Laurie Tylaska attended the University of Vermont from 1983 to 1985 where they studied Biochemistry/Microbiology. In 2011, they enrolled at the University of CT and completed a Certification program in Medical Laboratory Science in 2013.
This person is not in any offices
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.